South Australian Cancer Registry (Australia)

Database Contact Data

SA Cancer Registry
Contact: Helen Thomas
Email: helen.thomas2@sa.gov.au

Alternate Contact

SA Cancer Registry Manager
Email: WellbeingSACCSACancerRegistry@sa.gov.au

References of Studies Using/Describing Database

1. Tempo JA, Sii S, Ischia J, Bolton DM, D'Onise K, Meng R, Watson DI, O'Callaghan M. Lessons from a population‐based bladder cancer registry: exploring why survival is not improving. BJU international. 2024 Jun;133(6):699-708.

2. Mashtoub S, Ullah S, Collinson A, Singh GR, Clark J, Leemaqz S, Paltiel O, Roder DM, Saxon B, McKinnon R, Pandol SJ. Childhood Cancer Incidence and Survival in South Australia and the Northern Territory, 1990–2017, with Emphasis on Indigenous Peoples. Cancers. 2024 May 29;16(11):2057.

3. Tiruye T, Roder D, FitzGerald LM, O'Callaghan M, Moretti K, Caughey GE, Beckmann K. Impact of comorbidities on prostate cancer‐specific mortality: A population‐based cohort study. The Prostate. 2024 May 26.

4. Venugopal K, Youlden D, Te Marvelde L, Meng R, Aitken J, Evans S, Kostadinov I, Nolan R, Thomas H, D'Onise K. Twenty years of melanoma in Victoria, Queensland, and South Australia (1997–2016). Cancer Epidemiology. 2023 Apr 1;83:102321.

5. Gheybi K, Buckley E, Vitry A, Roder D. Associations of advanced age with comorbidity, stage and primary subsite as contributors to mortality from colorectal cancer. Frontiers in Public Health. 2023;11.

6. Lal A, Gao L, Tan E, McCaffrey N, Roder D, Buckley E. Long-term benefits for lower socioeconomic groups by improving bowel screening participation in South Australia: A modelling study. Plos one. 2022 Dec 21;17(12):e0279177.

7. Clark RA, Lui S. Does Cancer Treatment Break Your Heart? A Linked Health Data Analysis of Thecharacteristics and Survival of Patients Who Have Developed Cardiovascular Disease Post Cancer Treatment. Circulation. 2022 Nov 8;146(Suppl_1):A14602-.

8. Gheybi K, Buckley E, Vitry A, Roder D. Occurrence of comorbidity with colorectal cancer and variations by age and stage at diagnosis. Cancer Epidemiology. 2022 Oct 1;80:102246.

9. Beckmann K, Kearney AM BJ, Yeung D, Hiwase D, Li M, Roder DM. Changes in five‐year survival for people with acute leukaemia in South Australia, 1980–2016. Medical Journal of Australia. 2022 Apr 4;216(6):296-302.

10. Lal A, McCaffrey N, Gold L, Roder D, Buckley E. Variations in utilisation of colorectal cancer services in South Australia indicated by MBS/PBS benefits: a benefit incidence analysis. Australian and New Zealand Journal of Public Health. 2022 Apr;46(2):237-42.

Mar 15, 2021: Read about our newest database profile from IBM®

The IBM® MarketScan® Hospital Drug Database provides researchers with inpatient drug utilization data from hospital discharge records since 2002. This database is derived primarily from hospital billing systems from US hospitals. These data allow researchers to evaluate drug use in the inpatient and outpatient settings, including hospital use patterns, switching behavior, combination therapy and patient characteristics.

Merative MarketScan® Hospital Drug Database (USA) §

Database Contact Data

N/A

Alternate Contact

N/A

References of Studies Using/Describing Database

1: Keshishian A, Xie L, Dembek C, Yuce H. Reduction in Hospital Readmission Rates Among Medicare Beneficiaries With Chronic Obstructive Pulmonary Disease: A Real-world Outcomes Study of Nebulized Bronchodilators. Clin Ther. 2019 Nov;41(11):2283-2296. 

2: Mollard S, Lurienne L, Heimann SM, Bandinelli PA. Burden of Clostridium (Clostridioides) difficile infection during inpatient stays in the USA between 2012 and 2016. J Hosp Infect. 2019 Jun;102(2):135-140. 

3: Vallabhaneni S, Baggs J, Tsay S, Srinivasan AR, Jernigan JA, Jackson BR. Trends in antifungal use in US hospitals, 2006-12. J Antimicrob Chemother. 2018 Oct 1;73(10):2867-2875. 

4: Baggs J, Jernigan JA, Halpin AL, Epstein L, Hatfield KM, McDonald LC. Risk of Subsequent Sepsis Within 90 Days After a Hospital Stay by Type of Antibiotic Exposure. Clin Infect Dis. 2018 Mar 19;66(7):1004-1012.

5: Maiese BA, Pham AT, Shah MV, Eaddy MT, Lunacsek OE, Wan GJ. Hospitalization Costs for Patients Undergoing Orthopedic Surgery Treated With Intravenous Acetaminophen (IV-APAP) Plus Other IV Analgesics or IV Opioid Monotherapy for Postoperative Pain. Adv Ther. 2017 Feb;34(2):421-435. 

6: Margolis JM, Deitelzweig S, Kline J, Tran O, Smith DM, Crivera C, Bookhart B, Schein J. Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With Warfarin. Clin Ther. 2016 Nov;38(11):2496-2503. 

7: Baggs J, Fridkin SK, Pollack LA, Srinivasan A, Jernigan JA. Estimating National Trends in Inpatient Antibiotic Use Among US Hospitals From 2006 to 2012. JAMA Intern Med. 2016 Nov 1;176(11):1639-1648. 

8: Margolis JM, Deitelzweig S, Kline J, Tran O, Smith DM, Bookhart B, Crivera C, Schein J. Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions. J Am Heart Assoc. 2016 Oct 6;5(10).

9: Yi SH, Jernigan JA, McDonald LC. Prevalence of probiotic use among inpatients: A descriptive study of 145 U.S. hospitals. Am J Infect Control. 2016 May 1;44(5):548-53. 

10: Montejano L, Vo L, McMorrow D. Transitions of Care for People with Type 2 Diabetes: Utilization of Antihyperglycemic Agents Pre- and Post-Hospitalization. Diabetes Ther. 2016 Mar;7(1):91-103. 

Subscribe to